公开(公告)号：US20240425505A1

公开(公告)日：2024-12-26

申请号：US18817352

申请日：2024-08-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael E. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US12157733B2

公开(公告)日：2024-12-03

申请号：US17116016

申请日：2020-12-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04

Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US11866414B2

公开(公告)日：2024-01-09

申请号：US17743557

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman ,  Zili Xiao

IPC: C07D249/04 ,  A61P25/28 ,  A61P25/16 ,  A61K31/501

CPC classification number: C07D249/04 ,  A61K31/501 ,  A61P25/16 ,  A61P25/28

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US11440913B2

公开(公告)日：2022-09-13

申请号：US16758892

申请日：2018-10-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Michael E. Mertzman ,  Carolyn Diane Dzierba ,  Jason M. Guernon ,  Amy C. Hart ,  Guanglin Luo ,  John E. Macor ,  William J. Pitts ,  Jianliang Shi ,  Steven H. Spergel

IPC: A61K31/5025 ,  C07D487/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US12110290B2

公开(公告)日：2024-10-08

申请号：US18347703

申请日：2023-07-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael E. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,




are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US20240190829A1

公开(公告)日：2024-06-13

申请号：US18524426

申请日：2023-11-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman ,  Joseph A. Tino ,  Shoshana L. Posy ,  Sirish Kaushik Lakkaraju ,  Zili Xiao ,  James Kempson

IPC: C07D249/04 ,  A61K31/501 ,  A61P25/16 ,  A61P25/28

CPC classification number: C07D249/04 ,  A61K31/501 ,  A61P25/16 ,  A61P25/28

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20240109888A1

公开(公告)日：2024-04-04

申请号：US18347703

申请日：2023-07-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael E. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,




are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US11884650B2

公开(公告)日：2024-01-30

申请号：US17743615

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman

IPC: C07D401/14 ,  C07D401/12

CPC classification number: C07D401/14 ,  C07D401/12

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20230020273A1

公开(公告)日：2023-01-19

申请号：US17289269

申请日：2019-10-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  William J. Pitts ,  Michael E. Mertzman ,  Ryan M. Moslin ,  Trevor C. Sherwood ,  John L. Gilmore ,  Alaric J. Dyckman

IPC: C07D413/14 ,  C07B59/00 ,  C07D403/12 ,  C07D413/12 ,  C07D417/14 ,  C07D417/12 ,  C07D401/14 ,  C07D403/14

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US20220411384A1

公开(公告)日：2022-12-29

申请号：US17743557

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman ,  Joseph A. Tino ,  Shoshana L. Posy ,  Sirish Kaushik Lakkaraju ,  Zili Xiao ,  James Kempson

IPC: C07D249/04 ,  A61P25/16 ,  A61K31/501 ,  A61P25/28

Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.